-
Mashup Score: 8The evolving need and challenges to reach LDL-c targets in high-risk patients - PACE-CME - 8 month(s) ago
According to the latest registries the majority of high- and very high-risk patients do not accieve 2019 ESC/EAS recommended LDL-c goals. Kausik Ray discusses how LDL-c goal attainment can be improved.
Source: pace-cme.orgCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 18Pitavastatin to Prevent Cardiovascular Disease in HIV Infection | NEJM - 10 month(s) ago
Original Article from The New England Journal of Medicine — Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
Source: www.nejm.orgCategories: Cardiologists, Latest HeadlinesTweet-
Important question answered in this patient group. Nice editorial too. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection | NEJM https://t.co/sKSFew8jkM
-
-
Mashup Score: 1Inclisiran and cardiovascular events: a patient-level analysis of phase III trials - 11 month(s) ago
Exploratory findings from a patient-level, pooled analysis of the pivotal Phase III ORION trials (−9, −10, and −11) suggest that treatment with a 6 monthly dosi
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
RT @StefaniaArciell: Inclisiran and cardiovascular events: a patient-level analysis of phase III trials https://t.co/O97AEbgkkx
-
-
Mashup Score: 2EAS – European Atherosclerosis Society - 11 month(s) ago
EAS work continuously on the benefits we offer to our members, and the quality of the service we provide. We have transferred our member records to a new member platform, to modernise and make more effective the way we manage our members’ details.Members will now find it easier to manage their own profile and be able to access the resources that are included in membership, conveniently all in one…
Source: eas-society.orgCategories: Cardiologists, Latest HeadlinesTweet-
RT @BNordestgaard: Thanks to all who voted. Voting works if many take the time to cast their vote! https://t.co/wUbqSp3EHV @MeralKayikcoglu…
-
-
Mashup Score: 3EAS – European Atherosclerosis Society - 11 month(s) ago
EAS work continuously on the benefits we offer to our members, and the quality of the service we provide. We have transferred our member records to a new member platform, to modernise and make more effective the way we manage our members’ details.Members will now find it easier to manage their own profile and be able to access the resources that are included in membership, conveniently all in one…
Source: eas-society.orgCategories: Cardiologists, Latest HeadlinesTweet-
RT @BNordestgaard: URGENT - EAS voting ends June 30th. Please vote and re-tweet. I stand for President-Elect https://t.co/2xzFA33FPX @Meral…
-
-
Mashup Score: 3Management of severe hypertriglyceridemia – EAS - 12 month(s) ago
Featured Open Lecture: June-July, 2023Professor Marcello Arca is Head of the Lipid and Atherosclerosis Unit of the University Hospital Policlinico Umberto I in Rome and Professor of internal medicine at the Sapienza University of Rome Italy.His main field of interest relates to rare primary dyslipidemia. He has made important contributions to the treatment of HoFH, the phenotyping of ANGPTL3…
Source: eas-society.orgCategories: Cardiologists, Latest HeadlinesTweet-
RT @society_eas: June has arrived, and that means we have a new Open Lecture available for you. Click here: https://t.co/wkd7tIyY6L and fin…
-
-
Mashup Score: 6
AbstractAims. Long-term, placebo-controlled cholesterol-lowering trials have demonstrated legacy effects (clinical benefits that persist or emerge after trial e
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Extremely Low LDL-C earlier post ACS would tie in with Huygens and PACMAN. Our paper out now EHJ, from Odyssey outcomes ehad144, https://t.co/Wd9gYxDvvz
-
-
Mashup Score: 1Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes - 1 year(s) ago
This secondary analysis of the DECLARE-TIMI 58 trial evaluates whether N-terminal pro–B-type natriuretic peptide and high-sensitivity cardiac troponin T levels can identify a subset of patients with type 2 diabetes at higher risk and who might benefit more from dapagliflozin with regard to…
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
Our recent paper on the biomarkers in patients with DM and CVD JAMA Cardiol https://t.co/DZDJrtlH2W
-
-
Mashup Score: 1402 - Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials - 1 year(s) ago
Video Player is loading.Current Time 0:00Duration 0:00Loaded: 0%Stream Type LIVERemaining Time 0:001x2x1.75×1.5×1.25x1x, selected0.75×0.5xChaptersdescriptions off, selectedcaptions settings, opens captions settings dialogcaptions off, selectedEnglish, selectedAsk a QuestionSearchShare PresentationInfoShow Polls
Source: acc.mediasite.comCategories: Cardiologists, Latest HeadlinesTweet-
I'm excited about tomorrow. Aren't you? #Clear Outcomes Late Breaking Clinical Trial Presentation, Saturday March 4, 2023 from 9:30 a.m. – 9:42 a.m. CST: https://t.co/gi1IK9zvrw
-
-
Mashup Score: 0408 - Late-Breaking Clinical Trials Deep Dive I - 1 year(s) ago
Video Player is loading.Current Time 0:00Duration 0:00Loaded: 0%Stream Type LIVERemaining Time 0:001x2x1.75×1.5×1.25x1x, selected0.75×0.5xChaptersdescriptions off, selectedcaptions settings, opens captions settings dialogcaptions off, selectedEnglish, selectedAsk a QuestionSearchShare PresentationInfoShow Polls
Source: acc.mediasite.comCategories: Cardiologists, Latest HeadlinesTweet-
There's only so much that can be covered tomorrow. So perhaps a deeper dive is needed. CLEAR Outcomes Deep Dive, Sunday, March 5, 2020 from 2 p.m. – 2:05 p.m. CST: https://t.co/YMh5iXEQ7V
-
RT @PACEcme: The evolving need and challenges to reach LDL-c targets in high-risk patients. Watch: https://t.co/YDMfBw1iyz #LDL #Cardiotw…